1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

What’s Next? Five Things To Look Out For In April

Alvotech Eyes Further US Biosimilar Approval; Fresh Wave Of Price Cuts Hits Japan

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2024.

What's Next Image
• Source: Norstella/Citeline

Boosted by the recent US Food and Drug Administration approval for its Simlandi (adalimumab-ryvk) biosimilar –the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira – Alvotech will this month look to grab hold of in quick succession a further US biosimilar approval for autoimmune diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

More from Products